Home
Clinical Trials
A Study to Evaluate Avastin i...

A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer

Last Updated: 2013-06-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2000-09-30

Study Completion Date

2003-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a multicenter, Phase III, randomized, active-controlled trial to evaluate the efficacy and safety of rhuMAb VEGF (Avastin) added to the standard first-line chemotherapy used to treat metastatic colorectal cancer. This trial will enroll approximately 900 subjects with histologically confirmed, previously untreated, bi-dimensionally measurable metastatic colorectal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Avastin in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

NCT00109226

Colorectal Cancer

COMPLETED PHASE2

A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

NCT01181609

Colorectal Cancer

COMPLETED PHASE2

A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma

NCT00097578

Colorectal Cancer

COMPLETED

A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum

NCT02582970

Colorectal Cancer

COMPLETED PHASE4

A Study to Compare Two Avastin-Based Treatment Regimens for the Treatment of Metastatic Colorectal Cancer

NCT00114946

Colorectal Cancer

TERMINATED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Avastin (bevacizumab)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Written informed consent
* Age \>=18 years
* Histologically confirmed colorectal carcinoma with evidence of metastases (i.e., by radiographic imaging or biopsy)
* Ability to tolerate CT contrast dye
* Bi-dimensionally measurable disease (minimum of two lesions)
* ECOG performance status of 0 or 1
* Use of an effective means of contraception in women of childbearing potential
* Life expectancy of \>3 months
* Willingness and capability to be accessible for follow-up until death or study termination by Genentech

Exclusion Criteria

* Prior chemotherapy other than adjuvant fluoropyrimidines in combination with leucovorin and/or levamisole
* Administration of adjuvant fluoropyrimidines in combination with leucovorin and/or levamisole completed \<=12 months prior to Day 0
* Administration of fluoropyrimidines as a radiosensitizer during pelvic radiotherapy for rectal cancer completed \<=12 months prior to Day 0
* Prior radiotherapy to a measurable, metastatic lesion(s) to be used to measure response
* Radiation therapy within 14 days prior to Day 0
* Prior biotherapy for colorectal cancer
* Evidence of clinically detectable ascites on Day 0
* Other invasive malignancies within 5 years prior to Day 0 (other than basal cell carcinoma of the skin)
* History or evidence upon physical examination of CNS disease (e.g., primary brain tumor, seizures not controlled with standard medical therapy, any brain metastases, or history of stroke)
* Active infection requiring parenteral antibiotics on Day 0
* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study; fine needle aspirations within 7 days prior to Day 0
* Current or recent (within the 10 days prior to Day 0) use of full-dose oral or parenteral anticoagulants (except as required to maintain patency of preexisting, permanent indwelling IV catheters) or thrombolytic agent (for subjects receiving warfarin, international normalized ratio \[INR\] of \<1.5; appropriate use of heparin should be discussed with the Medical Monitor)
* Chronic, daily treatment with aspirin (\>325 mg/day) or nonsteroidal anti-inflammatory medications (of the kind known to inhibit platelet function at doses used to treat chronic inflammatory diseases)
* Pregnancy (positive pregnancy test) or lactation
* Proteinuria at baseline or clinically significant impairment of renal function
* Serious, nonhealing wound, ulcer, or bone fracture
* Evidence of bleeding diathesis or coagulopathy
* Current or recent (within the 28 days prior to Day 0) participation in another experimental drug study
* Clinically significant cardiovascular disease (e.g., uncontrolled hypertension, myocardial infarction, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication, or Grade II or greater peripheral vascular disease within 1 year prior to Day 0
* Screening clinical laboratory values: \*ANC of \<1500/uL; \*Platelet count of \<75,000/uL; \*INR of \>=1.5; \*Total bilirubin of \>1.6 mg/dL; \*AST or ALT \>=5 times upper limit of normal for subjects with documented liver metastases (\>2.5 times the upper limit of normal for subjects without evidence of liver metastases); \*Serum creatinine of \>2.0 mg/dL; \*Hemoglobin of \<9 gm/dL (may be transfused to maintain or exceed this level)
* History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates use of an investigational drug or that might affect interpretation of the results of the study or render the subject at high risk from treatment complications

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers